Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

This study has been completed.
Information provided by:
Angiochem Inc Identifier:
First received: October 2, 2007
Last updated: July 30, 2014
Last verified: July 2014